870706-51-7

Basic information

• Product Name: 5-BroMo-4-chloro-7-(triisopropylsilyl)-7H-pyrrolo[2,3-d]pyriMidine
• Synonyms: 5-BroMo-4-chloro-7-(triisopropylsilyl)-7H-pyrrolo[2,3-d]pyriMidine
• CAS NO: 870706-51-7
• Molecular Formula: C15H23BrClN3Si
• Molecular Weight: 388.80572
• Mol File: 870706-51-7.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5-BroMo-4-chloro-7-(triisopropylsilyl)-7H-pyrrolo[2,3-d]pyriMidine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-BroMo-4-chloro-7-(triisopropylsilyl)-7H-pyrrolo[2,3-d]pyriMidine(870706-51-7)
• EPA Substance Registry System: 5-BroMo-4-chloro-7-(triisopropylsilyl)-7H-pyrrolo[2,3-d]pyriMidine(870706-51-7)

Safety Data

• Hazardous Substances Data: 870706-51-7(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
5-Bromo-4-chloro-7-(triisopropylsilyl)-7H-pyrrolo[2,3-d]pyrimidine is used as a building block in organic synthesis for the creation of various chemical compounds. Its unique structure and reactivity make it a valuable tool in the development of new chemical entities.
Used in Medicinal Chemistry:
5-Bromo-4-chloro-7-(triisopropylsilyl)-7H-pyrrolo[2,3-d]pyrimidine is used as a building block in the synthesis of pharmaceutical drugs and bioactive molecules. Its potential as a precursor for the development of new drugs makes it an important compound in medicinal chemistry.
Used in the Development of Functional Materials:
5-Bromo-4-chloro-7-(triisopropylsilyl)-7H-pyrrolo[2,3-d]pyrimidine is used in the development of functional materials due to its unique structure and reactivity. Its potential applications in various industries make it a valuable compound for research and development.

Upstream product

• 870706-50-6 4-chloro-7-triisopropylsilanyl-7H-pyrrolo[2,3-d]pyrimidine 
• 13154-24-0 triisopropylsilyl chloride 
• 3680-69-1 4-chloro-1H-pyrrolo[2,3-d]pyrimidine 

Downstream Products

• 1350821-36-1 [4-amino-7-(propan-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl](6-{[(1R,2R)-2-phenylcyclopentyl]amino}pyrazin-2-yl)methanone 
• 1350821-37-2 (4-amino-7-isopropyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl){6-[(1R,2R)-2-(4-fluorophenyl)cyclopentylamino]pyrazin-2-yl}methanone 
• 1350821-38-3 (4-amino-7-isopropyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)(6-{[(1R,2R)-2-(4-fluorophenyl)cyclopentyl]methylamino}pyrazin-2-yl)methanone 
• 1350821-39-4 (4-amino-7-isopropyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl){6-[(3S,4R)-4-(4-fluorophenyl)tetrahydrofuran-3-ylamino]pyrazin-2-yl}methanone 
• 1350821-44-1 (4-amino-7-isopropyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl){6-[(2R,3R)-2-(4-fluorophenyl)pyrrolidin-3-ylamino]pyrazin-2-yl}methanone formate 
• 1350821-45-2 (2R,3R)-3-[6-(4-amino-7-isopropyl-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl)pyrazin-2-ylamino]-2-(4-fluorophenyl)pyrrolidine-1-carbaldehyde 
• 1350821-46-3 1-[(2R,3R)-3-[6-(4-amino-7-isopropyl-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl)pyrazin-2-ylamino]-2-(4-fluorophenyl)pyrrolidin-1-yl]ethanone 

Relevant articles and documents

Discovery of novel, potent, and selective inhibitors of 3-phosphoinositide-dependent kinase (PDK1)

Analogues substituted with various amines at the 6-position of the pyrazine ring on (4-amino-7-isopropyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)pyrazin-2- ylmethanone were discovered as potent and selective inhibitors of PDK1 with potential as anticancer agents. An early lead with 2-pyridine-3-ylethylamine as the pyrazine substituent showed moderate potency and selectivity. Structure-based drug design led to improved potency and selectivity against PI3Kα through a combination of cyclizing the ethylene spacer into a saturated, five-membered ring and substituting on the 4-position of the aryl ring with a fluorine. ADME properties were improved by lowering the lipophilicity with heteroatom replacements in the saturated, five-membered ring. The optimized analogues have a PDK1 Ki of 1 nM and >100-fold selectivity against PI3K/AKT-pathway kinases. The cellular potency of these analogues was assessed by the inhibition of AKT phosphorylation (T308) and by their antiproliferation activity against a number of tumor cell lines. (Figure presented)

PYRROLOPYRIMIDINE DERIVATIVES USEFUL IN CANCER TREATMENT

The invention relates to compounds of the formula (I) or a pharmaceutically acceptable salt, prodrug, solvate or hydrate thereof, wherein L, R', R2, R3 and R4 are as defined herein. The invention also relates to pharmaceutical compositions containing the compounds of formula (I) and to methods of treating abnormal cell growth, such as cancer in a mammal by administering the compounds of formula (I).